GlassScriptPhysician profile
George S Drew
NPI 1245298009
$1,933,192.76
in general payments reported to CMS, 2019-2025
49 companies · $396K in 2025
The $396K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147K · 2020: $86K · 2021: $124K · 2022: $265K · 2023: $469K · 2024: $445K · 2025: $396K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $841K · Consulting Fee: $228K · Travel and Lodging: $162K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $43K · Food and Beverage: $35K · Honoraria: $1,500 · Education: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $840,969.83 |
| Consulting Fee | $227,776.97 |
| Travel and Lodging | $161,550.52 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $43,005.00 |
| Food and Beverage | $34,737.26 |
| Honoraria | $1,500.00 |
| Education | $361.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $305,769.76 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $180,249.70 | 2019-2025 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $180,062.64 | 2021-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $168,604.21 | 2019-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $150,331.92 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $123,147.53 | 2019-2025 | Siliq, Cabtreo, Jublia |
| Genzyme Corporation | $116,173.74 | 2019-2025 | |
| Janssen Biotech, INC. | $114,447.06 | 2019-2025 | Tremfya, Stelara |
| Incyte Corporation | $108,404.38 | 2021-2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $72,207.20 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69,518.15 | 2022-2025 | Spevigo, Cyltezo |
| Dermavant Sciences, INC. | $64,754.36 | 2022-2024 | Vtama |
| Leo Pharma INC. | $63,877.33 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Sun Pharmaceutical Industries INC. | $55,184.87 | 2019-2025 | Ilumya |
| Galderma Laboratories, L.P. | $51,345.57 | 2019-2025 | Nemluvio |
Show all 46 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Drew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.